BioSpecifics Technology provides corporate update tadora 20 mg reviews.

BioSpecifics Technology provides corporate update, reports Q4 and FY 2014 financial outcomes BioSpecifics Technology Corp tadora 20 mg reviews http://tadora.biz .S. ‘Recently is a year of incredible development commercially for XIAFLEX. In the U.S., we saw a substantial upsurge in total XIAFLEX revenues in 2014, powered by the launch in Peyronie's disease. This boost was obvious in the royalties and mark-up on COGS revenues in 2014, which a lot more than doubled when compared to previous calendar year. Revenues exceeded goals and we are wanting to see rising product sales of XIAFLEX for sufferers in the U.S.